Results 11 to 20 of about 399,367 (396)

The chronic myeloid leukemia stem cell: stemming the tide of persistence. [PDF]

Blood, 2017
Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self-renews, proliferates, and differentiates to give rise to a ...
T. Holyoake, D. Vetrie
semanticscholar   +3 more sources

Blast crisis in chronic myeloid leukemia: An immunophenotypic analysis

International Journal of Science Annals, 2022
Background and Aim of Study: There are two different phases of untreated chronic myeloid leukemia – chronic phase, and blast crisis – according to the World Health Organization classification of Hematolymphoid tumors.
Singh Akanksha, Singh Anurag , Kanaujia Sweta , Kushwaha Rashmi , Singh Uma Shankar   +4 more
doaj   +1 more source

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]

, 2014
Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI, Greco M, LA NASA, GIORGIO   +2 more
core   +5 more sources

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Leukemia, 2020
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy.
A. Hochhaus, M. Baccarani, R. Silver, C. Schiffer, J. Apperley, F. Cervantes, R. Clark, J. Cortes, M. Deininger, F. Guilhot, H. Hjorth-Hansen, T. Hughes, J. Janssen, H. Kantarjian, Dong-Kee Kim, R. Larson, J. Lipton, F. Mahon, J. Mayer, F. Nicolini, D. Niederwieser, F. Pane, J. Radich, D. Réa, J. Richter, G. Rosti, P. Rousselot, G. Saglio, Susanne Saussele, S. Soverini, J. Steegmann, A. Turkina, A. Zaritskey, Ruediger Hehlmann   +33 more
semanticscholar   +1 more source

Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

Cells, 2021
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after ...
Valentina R Minciacchi, Rahul Kumar, D. Krause   +2 more
semanticscholar   +1 more source

Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase [PDF]

Vojnosanitetski Pregled, 2022
Introduction. Extramedullary sites of leukemic proliferation, harboring an adverse outcome, are rare and usually found in the blastic phase of chronic myeloid leukemia.
Sekulić Borivoj, Perčić Ivanka, Dragičević-Jojkić Marina, Dokić Marina, Panjković Milana   +4 more
doaj   +1 more source

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia [PDF]

Anais Brasileiros de Dermatologia, 2017
: Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites.
Erica Rodrigues de Araujo Vasconcelos, Alexander Richard Bauk, Mayra Carrijo Rochael   +2 more
doaj   +1 more source

Rare presentation and initial management of ischemic priapism in two cases of chronic myeloid leukemia

International Journal of Medicine and Health Development, 2021
Priapism is a rare clinical presentation in patients with chronic myeloid leukemia. Treatment involves multidisciplinary team efforts of the urologist and haemato-oncologist.
Musliu Adetola Tolani, Abdullahi Sudi, Bello Yusuf Jamoh, Ayodeji Olawale Afolayan, Asimiyu Adesina Opoola, Fatima Abdullahi Shehu   +5 more
doaj   +1 more source

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

New England Journal of Medicine, 2001
BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment ...
B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, J. Ford, N. Lydon, H. Kantarjian, R. Capdeville, Sayuri Ohno-Jones, C. Sawyers   +10 more
semanticscholar   +1 more source

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

New England Journal of Medicine, 2006
BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic ...
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. L. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson   +31 more
semanticscholar   +1 more source